Exome Asset Management LLC Acquires Shares of 258,391 Dyne Therapeutics, Inc. $DYN

Key Points

• Exome Asset Management LLC invested approximately $2.70 million in Dyne Therapeutics, acquiring 258,391 shares, which now represents 2.3% of their investment portfolio.
• Dyne Therapeutics has recently experienced a 6.5% decline in its stock price, with current trading at $13.30 and a market cap of $1.89 billion.
• Analysts have mixed opinions on the stock, with three rating it as a Strong Buy and others adjusting price targets, suggesting an average target of $34.07.

Exome Asset Management LLC purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 258,391 shares of the company's stock, valued at approximately $2,703,000. Dyne Therapeutics accounts for approximately 2.3% of Exome Asset Management LLC's investment portfolio, making the stock its 18th biggest position. Exome Asset Management LLC owned about 0.23% of Dyne Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Dyne Therapeutics by 5.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock worth $237,000 after purchasing an additional 1,115 shares in the last quarter. Arizona State Retirement System raised its stake in Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock worth $183,000 after buying an additional 1,481 shares during the period. E Fund Management Co. Ltd. boosted its holdings in Dyne Therapeutics by 16.2% in the first quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock worth $144,000 after acquiring an additional 1,923 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics in the fourth quarter worth approximately $50,000. Finally, GAMMA Investing LLC grew its stake in Dyne Therapeutics by 837.5% in the first quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock valued at $251,000 after acquiring an additional 2,345 shares during the period. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Stock Down 0.2%

DYN traded down $0.03 during mid-day trading on Friday, reaching $13.15. 2,028,284 shares of the stock were exchanged, compared to its average volume of 2,201,077. The company has a 50 day moving average price of $11.21 and a two-hundred day moving average price of $11.11. The stock has a market capitalization of $1.87 billion, a PE ratio of -3.41 and a beta of 1.10. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $37.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DYN. Raymond James Financial raised Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their target price for the stock from $31.00 to $35.00 in a research report on Monday, August 25th. Jones Trading started coverage on shares of Dyne Therapeutics in a report on Thursday, June 26th. They set a "buy" rating and a $30.00 price objective on the stock. Sanford C. Bernstein started coverage on shares of Dyne Therapeutics in a research note on Tuesday, June 24th. They issued a "market perform" rating and a $13.00 price objective on the stock. Stifel Nicolaus decreased their target price on shares of Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, July 31st. Finally, Chardan Capital dropped their price target on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $34.07.

Insider Buying and Selling

In other Dyne Therapeutics news, CEO John Cox sold 2,640 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $13.41, for a total value of $35,402.40. Following the completion of the sale, the chief executive officer owned 199,539 shares in the company, valued at approximately $2,675,817.99. This trade represents a 1.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 20.77% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.